• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by InspireMD Inc.

    5/24/23 4:31:51 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care
    Get the next $NSPR alert in real time by email
    SC 13G 1 d511558dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.    )*

     

     

    InspireMD, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    45779A846

    (CUSIP Number)

    May 16, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐

    Rule 13d-1(b)

     

      ☒

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 45779A846

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus Private Equity Fund III, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☒(1)

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      2,199,118 (2)

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      2,199,118 (2)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,199,118 (2)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

       9.9% (3)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN

    FOOTNOTES

     

    (1)

    The shares reported in this row are held by Soleus Private Equity Fund III, L.P. (“Soleus PE”). Soleus Private Equity GP III, LLC (“Soleus GP”) is the sole general partner of Soleus PE. Soleus PE GP III, LLC (“Soleus Manager”) is the sole manager of Soleus GP. Mr. Guy Levy is the sole managing member of Soleus Manager. Each of Mr. Guy Levy, Soleus Manager, and Soleus GP disclaims beneficial ownership of the securities held by Soleus PE, and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    Consists of shares of the common stock, par value $0.0001 per share (“Common Stock”), of InspireMD, Inc. (the “Issuer”) that are held by Soleus PE, or that may be acquired upon the exercise of warrants to purchase shares of Common Stock (“Warrants”) that are held by Soleus PE. The share numbers reflected in this report represent the maximum number of shares of Common Stock that may be held by the Reporting Persons as a result of the beneficial ownership limitations set forth in the Warrants.

    (3)

    This percentage is calculated based upon 21,192,204 shares of common stock outstanding of the Issuer as of May 19, 2023, as disclosed in the Issuer’s Registration Statement on Form S-3 that was filed with the Securities and Exchange Commission on May 23, 2023 (the “Form S-3”).


    CUSIP NO. 45779A846

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus Private Equity GP III, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☒(1)

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      2,199,118 (2)

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      2,199,118 (2)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,199,118 (2)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

       9.9% (3)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

    FOOTNOTES

     

    (1)

    The shares reported in this row are held by Soleus PE. Soleus GP is the sole general partner of Soleus PE. Soleus Manager is the sole managing member of Soleus GP. Mr. Guy Levy is the sole managing member of Soleus Manager. Each of Mr. Guy Levy, Soleus Manager, and Soleus GP disclaims beneficial ownership of the securities held by Soleus PE, and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    Consists of shares of the Common Stock of the Issuer that are held by Soleus PE, or that may be acquired upon the exercise of Warrants that are held by Soleus PE. The share numbers reflected in this report represent the maximum number of shares of Common Stock that may be held by the Reporting Persons as a result of the beneficial ownership limitations set forth in the Warrants.

    (3)

    This percentage is calculated based upon 21,192,204 shares of common stock outstanding of the Issuer as of May 19, 2023, as disclosed in the Form S-3.


    CUSIP NO. 45779A846

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus PE GP III, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☒(1)

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      2,199,118 (2)

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      2,199,118 (2)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,199,118 (2)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

       9.9% (3)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

    FOOTNOTES

     

    (1)

    The shares reported in this row are held by Soleus PE. Soleus GP is the sole general partner of Soleus PE. Soleus Manager is the sole managing member of Soleus GP. Mr. Guy Levy is the sole managing member of Soleus Manager. Each of Mr. Guy Levy, Soleus Manager, and Soleus GP disclaims beneficial ownership of the securities held by Soleus PE, and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    Consists of shares of the Common Stock of the Issuer that are held by Soleus PE, or that may be acquired upon the exercise of Warrants that are held by Soleus PE. The share numbers reflected in this report represent the maximum number of shares of Common Stock that may be held by the Reporting Persons as a result of the beneficial ownership limitations set forth in the Warrants.

    (3)

    This percentage is calculated based upon 21,192,204 shares of common stock outstanding of the Issuer as of May 19, 2023, as disclosed in the Form S-3.


    CUSIP NO. 45779A846

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Guy Levy

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☒(1)

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      2,199,118 (2)

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      2,199,118 (2)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,199,118 (2)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

       9.9% (3)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN

    FOOTNOTES

     

    (1)

    The shares reported in this row are held by Soleus PE. Soleus GP is the sole general partner of Soleus PE. Soleus Manager is the sole managing member of Soleus GP. Mr. Guy Levy is the sole managing member of Soleus Manager. Each of Mr. Guy Levy, Soleus Manager, and Soleus GP disclaims beneficial ownership of the securities held by Soleus PE, and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    Consists of shares of the Common Stock of the Issuer that are held by Soleus PE, or that may be acquired upon the exercise of Warrants that are held by Soleus PE. The share numbers reflected in this report represent the maximum number of shares of Common Stock that may be held by the Reporting Persons as a result of the beneficial ownership limitations set forth in the Warrants.

    (3)

    This percentage is calculated based upon 21,192,204 shares of common stock outstanding of the Issuer as of May 19, 2023, as disclosed in the Form S-3.


    Item 1.

     

      (a)

    Name of Issuer

    InspireMD, Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices

    4 Menorat Hamaor. St.

    Tel Aviv, Israel 6744832

    Item 2.

     

      (a)

    Name of Person(s) Filing

    Soleus Private Equity Fund III, L.P.

    Soleus Private Equity GP III, LLC

    Soleus PE GP III, LLC

    Guy Levy

     

      (b)

    Address of Principal Business Office or, if none, Residence

    Soleus Private Equity Fund III, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Soleus Private Equity GP III, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Soleus PE GP III, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Guy Levy

    c/o Soleus Capital Management, L.P

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

      (c)

    Citizenship

    Soleus Private Equity Fund III, L.P. – Delaware

    Soleus Private Equity GP III, LLC – Delaware

    Soleus PE GP III, LLC—Delaware

    Guy Levy – United States

     

      (d)

    Title of Class of Securities

    Common Stock, $0.0001 par value per share


      (e)

    CUSIP Number

    45779A846

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
             (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
      (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. ☐78c).
      (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
      (e)    ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
      (g)    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j)    ☐    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
      (k)    ☐    Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

    Item 4. Ownership.

    Reference is made to Items 5 – 11 on the preceding pages of this Schedule 13G.

    As the general partner of Soleus PE, Soleus GP may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the shares of Common Stock held by Soleus PE. As the sole manager of Soleus GP, Soleus Manager may be deemed to have shared power to vote or to direct the vote and to dispose or direct the disposition of the shares of Common Stock held by Soleus PE. As the sole managing member of Soleus Manager, Mr. Guy Levy may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the shares of Common Stock held by Soleus PE.

    Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that Mr. Levy, Soleus Manager, or Soleus GP is the beneficial owner of the shares of Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of their respective pecuniary interest therein, and such beneficial ownership is expressly disclaimed.

    Item 5. Ownership of Five Percent or Less of a Class

    Not applicable.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.


    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.

    Item 8. Identification and Classification of Members of the Group

    Not applicable.

    Item 9. Notice of Dissolution of Group

    Not applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose, or with the effect, of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: May 24, 2023     Soleus Private Equity Fund III, L.P.
        By:   Soleus Private Equity GP III, LLC, its General Partner
        By:   Soleus PE GP III, LLC, its Managing Manager
        By:   /s/ Guy Levy
        Name:   Guy Levy
        Title:   Managing Member
    Date: May 24, 2023     Soleus Private Equity GP III, LLC
        By:   Soleus PE GP III, LLC, its Managing Manager
        By:   /s/ Guy Levy
        Name:   Guy Levy
        Title:   Managing Member
    Date: May 24, 2023     Soleus PE GP III, LLC
        By:   /s/ Guy Levy
        Name:   Guy Levy
        Title:   Managing Member
    Date: May 24, 2023     /s/ Guy Levy
        Name:   Guy Levy

    Footnotes:    

    Attention:    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    Get the next $NSPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NSPR

    DatePrice TargetRatingAnalyst
    2/2/2026$6.00Buy
    Maxim Group
    More analyst ratings

    $NSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Gleason Shane Thomas sold $99,331 worth of shares (61,194 units at $1.62), decreasing direct ownership by 5% to 1,139,177 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    2/2/26 5:01:41 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Ward Scott R. was granted 88,053 shares, increasing direct ownership by 147% to 147,846 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    1/16/26 6:12:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Tommasoli Andrea was granted 226,695 shares, increasing direct ownership by 31% to 954,389 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    1/16/26 6:11:38 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on InspireMD with a new price target

    Maxim Group initiated coverage of InspireMD with a rating of Buy and set a new price target of $6.00

    2/2/26 7:53:56 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to one (1) new non-executive employee in the aggregate amount of 36,118 shares of restricted stock (the "Inducement Grants") outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of January 14, 2026, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants were granted u

    1/20/26 9:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

    The CGuard® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) MIAMI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that results from the Company's C-GUARDIANS pivotal trial have now been published in the Journal of the American College of Cardiology (JACC). The data demonstrate the safety and efficacy of carotid artery stenting (CAS) with the Company's MicroNet™ covered stent in patients with asymptomatic carotid stenosis. As shown at

    1/12/26 9:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

    MIAMI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, welcomes the recent presentation and publication of CREST-2 data which demonstrated positive clinical outcomes for carotid artery stenting (CAS) for patients with asymptomatic carotid stenosis. CREST-2 data was shown at The Society of Vascular and Interventional Neurology (SVIN) Annual Meeting and the Vascular and Endovascular Issues Techniques and Horizons (VEITH) Symposium on November 21, 2025. In conjunction, the CREST-2 study was published in the New England Journal of Medicine. CREST-2 showed that, amo

    11/24/25 7:30:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    SEC Filings

    View All

    InspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - InspireMD, Inc. (0001433607) (Filer)

    12/19/25 4:15:42 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by InspireMD Inc.

    S-8 - InspireMD, Inc. (0001433607) (Filer)

    11/18/25 4:15:40 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by InspireMD Inc.

    SCHEDULE 13G/A - InspireMD, Inc. (0001433607) (Subject)

    11/14/25 6:12:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stuka Paul bought $9,182 worth of shares (5,073 units at $1.81), increasing direct ownership by 1% to 391,628 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    12/11/25 4:05:09 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Stuka Paul bought $9,436 worth of shares (5,073 units at $1.86), increasing direct ownership by 1% to 388,918 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    12/8/25 4:05:12 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Stuka Paul bought $18,740 worth of shares (10,130 units at $1.85), increasing direct ownership by 3% to 383,845 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    12/5/25 4:05:02 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Leadership Updates

    Live Leadership Updates

    View All

    InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer

    MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention. "We are thrilled to have Dr. Soukas join InspireMD to help lead our clinical and medical organization with strategy and oversight at this pivotal time for the Company," said Marvin Slosman, Chief Executive Officer of InspireMD. "His expertise and clinical practice focus in carotid intervention and peripheral vascular disease offer valuable insight

    11/3/25 7:30:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

    MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. "We are pleased to welcome Dan to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "He brings extensive experience, financial expertise, and

    9/17/25 8:00:00 AM ET
    $BBNX
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

    MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. "We are thrilled to welcome Ray to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "We expect to benefit greatly from his vast insights and experience. His

    7/31/25 8:31:00 AM ET
    $KMTS
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Financials

    Live finance-specific insights

    View All

    InspireMD Reports Third Quarter 2025 Financial Results

    MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the third quarter and nine months ended September 30, 2025. Recent Business Highlights: Initiated U.S. commercial launch of the CGuard Prime carotid stent systemCompleted over 100 U.S. carotid procedures across leading hospitalsStrengthened leadership team with the appointment of Peter A. Soukas, M.D., as Chief Medical OfficerAppointed Dan Dearen to the Board of Directors as Audit Committee Chairman bringing valuable experience to InspireMD Marvin Slosma

    11/4/25 7:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD to Announce Third Quarter 2025 Financial Results

    MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by registering below. A replay of the webin

    10/21/25 4:05:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Reports Second Quarter 2025 Financial Results

    --- Management to host investor conference call today, August 5th, at 8:30am ET --- MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the second quarter and six months ended June 30, 2025. Recent Business Highlights: Received premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA) for the CGuard Prime carotid stent systemCommenced commercial launch of the CGuard Prime carotid stent system in the U.S. MarketRaised $58 million in gross proceeds from an equity private placement and the exercise of existin

    8/5/25 8:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by InspireMD Inc.

    SC 13G - InspireMD, Inc. (0001433607) (Subject)

    12/4/24 4:31:06 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

    11/14/24 6:35:20 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

    10/28/24 4:02:11 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care